Insulin Pork

drug
On this page

Also known as Insulin porcineInsulin porcine insulin

Summary

Insulin Pork (CHEMBL1201539) is an approved protein; indicated across 23 conditions including diabetes mellitus and coronary artery disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Protein
  • Indications: 23 conditions

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201539
NameInsulin Pork
TypeProtein
Max phase4

Also known as: Insulin porcine, Insulin porcine insulin, Insulin pork, INSULIN PORK

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

23 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
diabetes mellitus3MONDO:0005015EFO:0000400
coronary artery disorder3MONDO:0005010EFO:0001645
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
type 2 diabetes mellitus3MONDO:0005148MONDO:0005148
gestational diabetes3MONDO:0005406EFO:0004593
hyperglycemia3MONDO:0002909HP:0003074
bone fracture2MONDO:0005315EFO:0003931
Parkinson disease2MONDO:0005180MONDO:0005180
hyperlipidemia2MONDO:0021187MONDO:0021187
injury1MONDO:0021178EFO:0000546
obesity disorder1MONDO:0011122EFO:0001073
chronic progressive multiple sclerosis1MONDO:0005284EFO:0003840
relapsing-remitting multiple sclerosis1MONDO:0005314EFO:0003929
delirium1MONDO:0045057EFO:0009267
hyperinsulinism1MONDO:0002177HP:0000842
hypoglycemia1MONDO:0004946HP:0001943
severe acute respiratory syndrome1MONDO:0005091MONDO:0100096
carpal tunnel syndrome0MONDO:0007275EFO:0004143

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).